tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

NGNE Stock Latest News

Three new option listings and one option delisting on August 14th
The FlyThree new option listings and one option delisting on August 14th
1M ago
LL
NGNE
Neurogene’s NGN-401 Wins Key FDA Designation
PremiumCompany Announcements
Neurogene’s NGN-401 Wins Key FDA Designation
1M ago
NGNE
Neurogene’s NGN-401 Shows Promise for Rett Syndrome
PremiumCompany Announcements
Neurogene’s NGN-401 Shows Promise for Rett Syndrome
1M ago
NGNE
Neurogene price target lowered to $49 from $51 at H.C. Wainwright
PremiumThe Fly
Neurogene price target lowered to $49 from $51 at H.C. Wainwright
1M ago
NGNE
Neurogene reports Q2 EPS ($1.09), consensus ($1.05)
PremiumThe Fly
Neurogene reports Q2 EPS ($1.09), consensus ($1.05)
1M ago
NGNE
Neurogene announces RMAT designation for NGN-401
PremiumThe FlyNeurogene announces RMAT designation for NGN-401
1M ago
NGNE
Neurogene’s NGN-401 Granted RMAT Status for Rett Syndrome
Premium
Company Announcements
Neurogene’s NGN-401 Granted RMAT Status for Rett Syndrome
1M ago
8K
NGNE
One new option listing and eighteen option delistings on July 22nd
Premium
The Fly
One new option listing and eighteen option delistings on July 22nd
2M ago
TIL
BKYI
Neurogene to be added to Russell 3000 Index July 1
PremiumThe Fly
Neurogene to be added to Russell 3000 Index July 1
3M ago
NGNE
Neurogene initiated with an Outperform at BMO Capital
PremiumThe Fly
Neurogene initiated with an Outperform at BMO Capital
3M ago
NGNE
Neurogene Releases Updated Corporate Presentation Online
PremiumCompany Announcements
Neurogene Releases Updated Corporate Presentation Online
3M ago
8K
NGNE
Neurogene negative reaction to competitor data ‘overblown,’ says William Blair
PremiumThe Fly
Neurogene negative reaction to competitor data ‘overblown,’ says William Blair
3M ago
NGNE
TSHA
Neurogene’s Rett Syndrome Trial Shows Promise
PremiumCompany AnnouncementsNeurogene’s Rett Syndrome Trial Shows Promise
3M ago
NGNE
Neurogene announces first patient dosed in high-dose cohort of NGN-401
Premium
The Fly
Neurogene announces first patient dosed in high-dose cohort of NGN-401
3M ago
NGNE
Neurogene initiated with an Outperform at Baird
Premium
The Fly
Neurogene initiated with an Outperform at Baird
3M ago
NGNE
Neurogene’s NGN-401 Therapy Advances under FDA START Program
PremiumCompany Announcements
Neurogene’s NGN-401 Therapy Advances under FDA START Program
4M ago
8K
NGNE
FDA accepts Neurogene’s NGN-401 gene therapy for Rett into START Pilot program
PremiumThe Fly
FDA accepts Neurogene’s NGN-401 gene therapy for Rett into START Pilot program
4M ago
NGNE
Taysha Gene Therapies assumed at Buy from Hold at Jefferies
PremiumThe Fly
Taysha Gene Therapies assumed at Buy from Hold at Jefferies
4M ago
NGNE
TSHA
Neurogene price target lowered to $51 from $55 at H.C. Wainwright
PremiumThe Fly
Neurogene price target lowered to $51 from $55 at H.C. Wainwright
4M ago
NGNE
Neurogene Inc. Optimistic on NGN-401 Trial Progress
PremiumCompany AnnouncementsNeurogene Inc. Optimistic on NGN-401 Trial Progress
4M ago
NGNE
Neurogene reports Q1 EPS ($1.00), consensus ($1.13)
Premium
The Fly
Neurogene reports Q1 EPS ($1.00), consensus ($1.13)
4M ago
NGNE
Neurogene Reveals Encouraging Gene Therapy Trial Results
Premium
Company Announcements
Neurogene Reveals Encouraging Gene Therapy Trial Results
5M ago
8K
NGNE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >